Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2018-08-13 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
107年第2季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple periods, including specific dates (e.g., 107年06月30日, 106年12月31日, 106年06月30日) and amounts in New Taiwan Dollars. The presence of comprehensive financial statements with asset, liability, and equity breakdowns indicates this is a financial report rather than a brief announcement or certification. The document length is 4074 characters, which is relatively short but contains substantive financial data. The content corresponds to an interim or quarterly financial report rather than a full annual report, as it covers a specific quarter (second quarter of year 107 in the Taiwanese calendar, which corresponds to 2018). There is no indication that this is an announcement of a report or a certification. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q2 2018
2018-08-13 Chinese
107年第2季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data specifically a consolidated statement of changes in equity for the first half of the year 2018 (民國107年上半年度) and the same period in the previous year. It includes line items such as common stock, capital surplus, legal surplus reserve, undistributed earnings, and total equity attributable to the parent company and non-controlling interests. The presence of actual financial figures and comparative periods indicates this is a substantive financial report for a period shorter than a full fiscal year. The document length is 3774 characters, which is relatively short but contains detailed financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-13 Chinese
107年7月營業收入
Interim / Quarterly Report Classification · 85% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 景岳, with data for July of the 107th year of the Republic of China calendar (which corresponds to 2018). It includes comparative figures from the previous year and percentage changes. The document is short (768 characters) and contains financial data but is not a comprehensive financial report. It appears to be a periodic revenue summary rather than a full interim or annual report. There is no indication that this is an announcement of a report publication or a certification. Given the nature of the data (monthly revenue figures) and the absence of detailed financial statements or analysis, this fits best as an Interim / Quarterly Report (IR) type, as it provides substantive financial data for a period shorter than a full fiscal year. Q2 2018
2018-08-10 Chinese
107年7月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 景岳, providing information about fund loans and endorsement guarantees for the current and previous months, with amounts all zero. The content is very short (601 characters) and consists mainly of tabular data about financial guarantees and loans, without detailed financial statements or analysis. It does not contain any narrative, management discussion, or comprehensive financial data. It is a regulatory disclosure of specific financial information but not a full report. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-08-10 Chinese
修正公告本公司投資子公司景岳生物科技(中國)有限公司
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from a listed company (3164 景岳) regarding an investment transaction involving its subsidiary 景岳生物科技(中國)有限公司. It details the investment amount, transaction dates, approval by the board, and other related financial and corporate information. The document is relatively short (2067 characters) and does not contain comprehensive financial statements or detailed financial performance data. It is an announcement of a capital investment transaction rather than a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-08-10 Chinese
公告本公司107年8月10日董事會通過之重要議案
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (景岳生物科技股份有限公司) dated 107/08/10 (Taiwan calendar year, equivalent to 2018) reporting on important resolutions passed at a board meeting. It specifically mentions the approval of the company's Q2 financial report and an investment amendment. The document is only 620 characters long and does not contain the actual financial statements or detailed financial data, but rather a summary of board decisions. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement of board resolutions and financial report approval, not the full interim report itself. The document is too short and does not contain substantive financial data to be classified as an Interim/Quarterly Report (IR).
2018-08-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.